sorafenib has been researched along with ponatinib in 21 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ponatinib) | Trials (ponatinib) | Recent Studies (post-2010) (ponatinib) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 538 | 34 | 519 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 14 (66.67) | 24.3611 |
2020's | 7 (33.33) | 2.80 |
Authors | Studies |
---|---|
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Song, M | 1 |
Adeniji-Popoola, O; Blagg, J; Blaukat, A; Box, G; Clarke, PA; Court, W; Czodrowski, P; Dale, T; de Haven Brandon, A; Eccles, SA; Esdar, C; Ewan, K; Fraser, E; Gowan, S; Mallinger, A; Musil, D; Ortiz-Ruiz, MJ; Poeschke, O; Raynaud, F; Rohdich, F; Samant, RS; Schiemann, K; Schneider, K; Schneider, R; Schwarz, D; Stubbs, M; TePoele, R; Valenti, M; Waalboer, D; Wienke, D; Workman, P | 1 |
Bestgen, B; Borjini, N; Chevé, G; Daydé-Cazals, B; Fauvel, B; Feneyrolles, C; Gassiot, F; Singer, M; Spenlinhauer, A; Van Hijfte, N; Warnault, P; Yasri, A | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Al-Ansary, GH; Al-Rashood, ST; Ali, MM; El Kerdawy, AM; Eldehna, WM; Mahmoud, AE | 1 |
Chen, F; Zhuang, C | 1 |
He, G; Jin, Y; Li, K; Lin, J; Liu, F; Xie, M; Yu, W; Zhang, C; Zhang, J; Zhao, Y; Zhu, C | 1 |
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
Acharya, B; Frett, B; Garcia, NG; Lakkaniga, NR; Ryan, KR; Saha, D; Smith, EL | 1 |
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E | 1 |
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X | 1 |
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG | 1 |
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F | 1 |
Fulda, S | 1 |
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
9 review(s) available for sorafenib and ponatinib
Article | Year |
---|---|
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Topics: Animals; Cell Line, Tumor; Drug Development; Humans; Molecular Structure; Necroptosis; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases | 2020 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Development; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret | 2021 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
12 other study(ies) available for sorafenib and ponatinib
Article | Year |
---|---|
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Kinesins; Lung Neoplasms; Models, Molecular; Protein Conformation | 2015 |
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Topics: Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase 8; Cyclin-Dependent Kinases; Humans; Models, Molecular; Molecular Probes; Molecular Structure; Protein Kinase Inhibitors; Pyridines; Spiro Compounds | 2015 |
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
Topics: Animals; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Mice; Patch-Clamp Techniques; Protein Kinase Inhibitors | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel ind
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Indoles; Models, Molecular; Oxindoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Structure-Activity Relationship; Sunitinib; TYK2 Kinase; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking.
Topics: Aniline Compounds; Humans; Molecular Docking Simulation; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib | 2013 |
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib | 2018 |